Aman Ali, MD
Gastroenterology · Edwardsville, PANPI 1093908113
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $149,599 of the $173,892 with a category attached, or 86.0%. 30 manufacturers reported payments, led by Sanofi at 31.7% of the total. Among gastroenterology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 330 payments — averaging $526.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$55K
- Regeneron Healthcare Solutions, Inc.$47K
- AbbVie$42K
- Phathom Pharmaceuticals, Inc.$25K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Ferring Pharmaceuticals Inc.$546
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$149,59986%
- Travel & lodging$16,3949%
- Food & beverage$7,8785%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 24 | $55,063 |
| Regeneron Healthcare Solutions, Inc. | 26 | $46,713 |
| AbbVie | 109 | $42,480 |
| Phathom Pharmaceuticals, Inc. | 22 | $24,566 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $2,067 |
| Ferring Pharmaceuticals Inc. | 39 | $546 |
| Novartis | 19 | $390 |
| Fujifilm Healthcare Americas Corporation | 6 | $357 |
| Novo Nordisk | 4 | $282 |
| Pfizer | 13 | $211 |
| Boston Scientific | 3 | $135 |
| W. L. Gore & Associates, Inc. | 1 | $134 |
| Johnson & Johnson | 8 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $122 |
| Gilead | 6 | $111 |
| Ardelyx, Inc. | 4 | $94 |
| Ironwood Pharmaceuticals, Inc | 5 | $74 |
| Bristol Myers Squibb | 4 | $60 |
| Medtronic | 2 | $54 |
| Intercept Pharmaceuticals, Inc. | 3 | $53 |
| Daiichi Sankyo Inc. | 4 | $50 |
| UCB, Inc. | 2 | $50 |
| Merck | 3 | $38 |
| Nestle Healthcare Nutrition Inc. | 2 | $25 |
| Boehringer Ingelheim | 1 | $19 |
| Redhill Biopharma Inc. | 1 | $17 |
| Braintree Laboratories, Inc. | 1 | $17 |
| Shionogi Inc | 1 | $15 |
| Endogastric Solutions, Inc | 1 | $14 |
| Axonics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$173,892 in reported general payments places this provider in the 95th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 12 | $324,171 |
| CreonLipase/Protease/Amylase | 97 | $266,819 |
| Humira PenAdalimumab | 13 | $171,709 |
| Mesalamine | 129 | $54,307 |
| ZenpepLipase/Protease/Amylase | 13 | $39,059 |
| LinzessLinaclotide | 56 | $35,898 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 77 | $12,999 |
| Lubiprostone | 65 | $11,836 |
| Omeprazole | 938 | $11,400 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 63 | $8,542 |
| Pantoprazole Sodium | 486 | $6,707 |
| Mesalamine ErMesalamine | 24 | $6,289 |
| Pyridostigmine Bromide | 19 | $5,550 |
| Famotidine | 407 | $4,940 |
| Ursodiol | 25 | $3,688 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $122 | $324,17112 claims |
| AbbVieCreon, Linzess | $42,480 | $302,717153 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $546 | $12,99977 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $2,067 | $8,54263 claims |
| Braintree Laboratories, Inc.Sutab | $17 | $2,04113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 935 gastroenterology providers in Pennsylvania.
Other gastroenterology in Edwardsville
- Miguel RegueiroPittsburgh$1.5M
- Adam PeytonAllentown$985K
- Shahin RahimianWaynesboro$592K
- Sandra El-HachemPittsburgh$472K
- Harshit KharaDanville$438K
- Kofi ClarkeHershey$426K
- Michael KochmanPhiladelphia$361K
- Gary LichtensteinPhiladelphia$342K
- Elie AounPittsburgh$323K
- Andrew TinsleyHershey$322K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.